Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer

Table 2

Concentrations of SCCA, NSE, CEA, and CYFRA21-1 in serum (ng/mL, 𝑥±𝑠).

Group	Number	SCCA	NSE	CEA	CYFRA21-1
Lung cancer	132	1.73±3.98^∗	19.45±14.47^∗∗★	17.81±35.79^∗∗★★	6.54±7.36^∗∗★★
Pulmonary benign disease	48	0.38±0.55	10.88±1.87	1.13±0.24^∗∗	1.72±0.83^∗∗
Healthy control	92	0.17±0.10	9.09±2.81	0.78±0.30	1.03±0.52

P value was calculated by Student’s t-test ∗compared to healthy control, 𝑃<0.05; ∗∗compared to healthy control, 𝑃<0.01.
★compared to pulmonary benign disease, 𝑃<0.05; ★★compared to pulmonary benign disease, 𝑃<0.01.